Dr. Gina D’Amato
Dr. Gina D’Amato, who appeared recently as moderator and contributor for the first Women in Sarcoma discussion panel, recorded a video discussing the use of liquid biopsy in sarcoma on OncTV for OncLive.
From the OncLive website:
OncLive is the official Website for the Oncology Specialty Group, which publishes OncologyLive, Urologists in Cancer Care, and Oncology Nursing News. Their mission is to provide oncology professionals with the resources and information they need to provide the best patient care. Dr. D’Amato is an associate professor and assistant director of Clinical Research at Sylvester Comprehensive Cancer Center, University of Miami.
In the sarcoma space, liquid biopsy is promising, D’Amato says. Prior to FDA approval, the Guardant360 CDx assay was utilized in sarcoma, mainly for patients with gastrointestinal stromal tumors. Additionally, the test was used in patients who had disease progression where tissue was unavailable for testing, explains D’Amato. Liquid biopsy may have a higher accuracy rate compared with tissue biopsy, D’Amato explains. However, until the technology improves, liquid biopsy will not be used in the adjuvant setting. Currently, patients have to have high tumor burden in order for an alteration to be detected.
View other posts/videos on Dr. D’Amato and her work.
View the First Women in Sarcoma webinar, moderated by Dr. D’Amato
More information on the Women in Sarcoma Program by the Life Raft Group
